menu search

AURA / JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer"

JMP Is Bullish On This Cancer Stock
JMP Securities has initiated the coverage on Aura Biosciences Inc (NASDAQ: AURA) with a Market Outperform rating and a $26 risk-adjusted price target. Aura is developing a targeted virus-like drug conjugate (VDC) technology platform that could establish a new standard of. Read More
Posted: Jul 19 2022, 15:06
Author Name: Benzinga
Views: 091195

AURA News  

Why Shares of Aura Biosciences Jumped This Week

By The Motley Fool
February 10, 2023

Why Shares of Aura Biosciences Jumped This Week

The clinical-stage biotech may be ready to release updated phase 3 trial results on its lead therapy. more_horizontal

JMP Is Bullish On This Cancer Stock

By Benzinga
July 19, 2022

JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer"

JMP Securities has initiated the coverage on Aura Biosciences Inc (NASDAQ: AURA) with a Market Outperform rating and a $26 risk-adjusted price ta more_horizontal


Search within

Pages Search Results: